← All trials
NCT01011439
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2009
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Tiziana Life Sciences, PLCLead sponsor
- National Cancer Institute (NCI)Overall official - principal investigator
- HOPITAL LARREY - TOULOUSEOverall official - principal investigator
- Institut Gustave RoussyOverall official - principal investigator
- University of TurinOverall official - principal investigator
- Scottsdale HealthcareOverall official - principal investigator
- Nerviano Medical SciencesStudy director
- University of MilanOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.